0001140361-24-036399.txt : 20240808 0001140361-24-036399.hdr.sgml : 20240808 20240808161034 ACCESSION NUMBER: 0001140361-24-036399 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240808 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240808 DATE AS OF CHANGE: 20240808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC. CENTRAL INDEX KEY: 0001368514 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 562590442 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36728 FILM NUMBER: 241188383 BUSINESS ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 BUSINESS PHONE: (201) 478-5552 MAIL ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 FORMER COMPANY: FORMER CONFORMED NAME: R&R ACQUISITION VI, INC DATE OF NAME CHANGE: 20060707 8-K 1 ef20033774_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 8, 2024
 
ADMA BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)

Delaware
001-36728
56-2590442
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

465 State Route 17, Ramsey, New Jersey
  
07446
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: (201) 478-5552
 
 
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Stock
ADMA
Nasdaq Global Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
Item 2.02
Results of Operations and Financial Condition

On August 8, 2024, ADMA Biologics, Inc. issued a press release announcing its financial results for the three months ended June 30, 2024, and provided a business update. A copy of the press release is furnished herewith as Exhibit 99.1.*

Item 9.01
Exhibits.
 
(d) Exhibits
 
Exhibit No.
Description
ADMA Biologics, Inc. Press Release, dated August 8, 2024
104
Cover Page Interactive Data File (embedded with the Inline XBRL document)
 
* The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

2
 SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
August 8, 2024
ADMA Biologics, Inc.
   
 
By:
/s/ Adam S. Grossman
   
Name:
Adam S. Grossman
   
Title:
President and Chief Executive
Officer


3
 EX-99.1 2 ef20033774_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1



ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update
 
2Q 2024 Total Revenue of $107.2 Million, a 78% Increase Y-o-Y
 
2Q 2024 GAAP Net Income of $32.1 Million, a $38.4 Million Increase Y-o-Y
 
2Q 2024 Adjusted EBITDA(1) of $44.5 Million, a Nearly 600% Increase Y-o-Y
 
Commercial Scale Production of ADMA’s Innovative Biologics Manufacturing Process Supports a Potential Yield Enhancement of Approximately 20% from Same Starting Plasma
 
FY 2024 and 2025 Total Revenue Guidance Increased to More Than $400 Million and $445 Million, Respectively
 
FY 2024 GAAP Net Income Guidance Increased to More Than $105 Million and Adjusted EBITDA Guidance Increased to More Than $150 Million
 
FY 2025 GAAP Net Income Guidance Increased to More than $155 Million and Adjusted EBITDA Guidance Increased to More Than $200 Million
 
Conference Call Scheduled for Today at 4:30 p.m. ET

RAMSEY, N.J. and BOCA RATON, FL, August 8, 2024 - ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its second quarter 2024 financial results and provided a business update.
 
“ADMA’s excellent second quarter results showcased the strength of our operations, innovative business and product offerings, enabling the Company to significantly increase both 2024 and 2025 financial guidance,” said Adam Grossman, President and Chief Executive Officer of ADMA. “We believe the Company is well-positioned to further strengthen its balance sheet, reduce the cost of capital and sustain ADMA’s position as one of the fastest growing and profitable companies in the biotech and pharma sector.”
 
Mr. Grossman continued, “ADMA’s commitment to serving immunodeficient patients, particularly those with complex comorbidities, remains the cornerstone of our mission. We see additional opportunities for ADMA to continue to grow substantially in the underserved, immune compromised and co-morbid patient population despite the availability of standard of care therapy. We are confident that incremental additional penetration with ASCENIV will accelerate near-term revenue growth and create a substantial peak revenue opportunity beyond our 2025 guided baseline. Looking to the remainder of 2024, we expect continued revenue and earnings growth, advancement of regulatory processes for manufacturing yield enhancement, favorable product mix shifts, and progress in our R&D programs.”
 
Second Quarter 2024 Milestones and Objectives:
 

 •
Compounding Growth. Driven by 78% year-over-year revenue growth, ADMA grew Adjusted EBITDA and Net Income to $44.5 million and $32.1 million, respectively, during the second quarter. On a quarter-over-quarter basis, Adjusted EBITDA grew 69% and Net Income grew 80% compared to the first quarter of 2024. The Company anticipates building on this momentum throughout the remainder of 2024 and beyond.
 
(1) Adjusted EBITDA is a non-GAAP financial measure. For a reconciliation of Adjusted EBITDA to the most comparable GAAP measure, please see the reconciliation included in the financial tables.

•
Favorably Evolving Mix Shift.  ADMA’s higher margin product portfolio now accounts for over 50% of the Company’s total revenue. ADMA is actively implementing measures to increase ASCENIV supply. If successful, these initiatives could enable ASCENIV to contribute a significant majority of ADMA’s total revenue over time, further advancing the Company’s potential margin expansion and earnings growth.
 

 •
Strengthened Balance Sheet.  Based on ADMA’s second quarter operating cash flow of $45.6 million and Adjusted EBITDA growth, the Company’s current net leverage ratio has organically improved to approximately 0.26x. The Company anticipates continued strengthening of the balance sheet driven by forecasted Adjusted EBITDA growth and ongoing cash generation in the second half of 2024 and beyond.
 

 •
Updated Marketing Materials. During the second quarter, ADMA revamped its corporate website, product websites and certain marketing materials, including those for Healthcare Providers (HCP).  Additionally, the Company released a new video testimonial on the ASCENIV product website, highlighting the treatment journey of a co-morbid and refractive immunodeficient patient.
 

 •
Expanded ADMAlytics™ Implementation. ADMA successfully expanded implementation of ADMAlytics to the commercial arm of the organization during the second quarter. When fully implemented, ADMAlytics is expected to further optimize the Company’s commercial growth strategy. Initiated in February 2024, the staggered implementation of ADMAlytics continues to yield impressive results across multiple areas of ADMA’s operations. These benefits include increased production efficiency, enhanced visibility into the 7–12-month manufacturing process, optimized commercial planning, streamlined plasma pooling, and reduced variability and FTE hours. These efficiencies are expected to further solidify ADMA’s rapid earnings growth outlook.
 
Upwardly Revised 2024-2025 Financial Guidance:
 

 •
FY 2024 and 2025 total revenue is now expected to be more than $400 million and $445 million, respectively, increased from prior guidance of more than $355 million and $410 million, respectively.
 

 •
FY 2024 and 2025 net income is now expected to exceed $105 million and $155 million, respectively, increased from prior guidance of $85 million and $135 million, respectively.
 

 •
FY 2024 and 2025 Adjusted EBITDA is now expected to exceed $150 million and $200 million, respectively, increased from prior guidance of $110 million and $160 million, respectively.
 
Advancing Innovative Growth Opportunities: Below are the Company’s ongoing initiatives which, if successful, we believe represent the potential for upside to our current forecasted guidance:
 

 •
Biologic Production Yield Enhancement: During the second quarter and recent periods, commercial-scale production of ADMA’s innovative biologics manufacturing process demonstrated a potential enhancement of yields by approximately 20% from the same starting plasma. If successful, we believe these yield improvements could significantly boost the Company’s future peak financial targets, potentially as early as the fourth quarter of 2025.
 

•
R&D Program - S. pneumonia Hyperimmune Globulin: Streptococcus pneumoniae is the leading cause of community-acquired pneumonia in the U.S., with about one million adults developing pneumococcal pneumonia annually, resulting in 400,000 hospitalizations and a 5-7% mortality rate. Despite vaccines, vaccine-naive and immune-compromised individuals remain at risk. A hyperimmune globulin could provide immediate antibodies, potentially generating $300-500 million annually if approved. ADMA holds various U.S. and foreign patents which cover its proprietary pneumococcal hyperimmune technology, including hyperimmune anti-pneumococcal immune globulin, preparation methods, and its use in treating S. pneumonia infections.
 

 •
ASCENIV Label Expansion: The ongoing post-marketing pediatric clinical study for ASCENIV may provide label expansion opportunities, further strengthening ADMA’s product portfolio, if successful.
 
Second Quarter 2024 Financial Results:
 
Total revenues were $107.2 million for the quarter ended June 30, 2024, as compared to $60.1 million for the quarter ended June 30, 2023, an increase of $47.1 million, or approximately 78%. The increase is primarily related to increased sales of ASCENIV. During the second quarter, the Company recognized a non-recurring, $12.6 million increase to net revenues and a corresponding reduction of an accrual related to a change in estimate for U.S. Medicaid rebates.

Gross profits were $57.5 million for the quarter ended June 30, 2024, as compared to $16.7 million for the quarter ended June 30, 2023, an increase of $40.8 million. As a result, ADMA achieved a corporate gross margin of 53.6% in the second quarter of 2024 as compared to 27.8% in the second quarter of 2023.

Adjusted EBITDA was $44.5 million for the quarter ended June 30, 2024, as compared to Adjusted EBITDA of $6.4 million for the quarter ended June 30, 2023, an increase of $38.1 million, or approximately 592%.

GAAP Net income was $32.1 million for the quarter ended June 30, 2024, compared to a GAAP Net Loss of $6.4 million for the quarter ended June 30, 2023.

As of June 30, 2024, ADMA had working capital of approximately $259.5 million, primarily consisting of $179.8 million of inventory, $88.2 million of cash and cash equivalents and $30.1 million of net accounts receivable, partially offset by current liabilities of $44.2 million.
 
Conference Call Information
 
To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who are not speaking during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts.
 
About ASCENIV™
 
ASCENIV (immune globulin intravenous, human – slra 10% liquid) is a plasma-derived, polyclonal, intravenous immune globulin (IVIG). ASCENIV was approved by the United States Food and Drug Administration (FDA) in April 2019 and is indicated for the treatment of primary humoral immunodeficiency (PI), also known as primary immune deficiency disease (PIDD), in adults and adolescents (12 to 17 years of age). ASCENIV is manufactured using ADMA’s unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma and respiratory syncytial virus (RSV) plasma obtained from donors tested using the Company’s proprietary microneutralization assay. ASCENIV contains naturally occurring polyclonal antibodies, which are proteins that are used by the body’s immune system to neutralize microbes such as bacteria and viruses that safeguard against infection and disease. ASCENIV is protected by numerous issued patents in the United States and internationally and a wide range of patent applications worldwide. Certain data and other information about ASCENIV can be found by visiting www.asceniv.com. Information about ADMA and its products can be found on the Company’s website at www.admabiologics.com.

Additional Important Safety Information About ASCENIV™
 
WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE
 
Thrombosis may occur with immune globulin intravenous (IGIV) products, including ASCENIV. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
 
Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients.
 
Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. ASCENIV does not contain sucrose.
 
For patients at risk of thrombosis, renal dysfunction or renal failure, administer ASCENIV at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

ASCENIV™ Contraindications:
 
History of anaphylactic or severe systemic reactions to human immunoglobulin.
 
IgA deficient patients with antibodies to IgA and a history of hypersensitivity.
 
ASCENIV™ Warnings and Precautions:
 
IgA-deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions. Have medications such as epinephrine available to treat any acute severe hypersensitivity reactions. [4, 5.1]
 
Thrombotic events have occurred in patients receiving IGIV treatments. Monitor patients with known risk factors for thrombotic events; consider baseline assessment of blood viscosity for patients at risk of hyperviscosity. [5.2, 5.4]
 
In patients at risk of developing acute renal failure. monitor renal function, including blood urea nitrogen (BUN), serum creatinine, and urine output. [5.3, 5.9]
 
Hyperproteinemia, increased serum viscosity, and hyponatremia or pseudohyponatremia can occur in patients receiving IGIV treatment.
 
Aseptic meningitis syndrome (AMS) has been reported with IGIV treatments, especially with high doses or rapid infusion. [5.5]
 
Hemolytic anemia can develop subsequent to IGIV treatment. Monitor patients for hemolysis and hemolytic anemia. [5.6]
 
Monitor patients for pulmonary adverse reactions (Transfusion-related acute lung injury [TRALI]). If transfusion related acute lung injury is suspected, test the product and patient for antineutrophil antibodies. [5.7]
 
Because this product is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
 
ASCENIV™ Adverse Reactions:
 
The most common adverse reactions to ASCENIV (≥5% of study subjects) were headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, and nausea
 
To report SUSPECTED ADVERSE REACTIONS, contact ADMA Biologics at (800) 458-4244 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
 
About ADMA Biologics, Inc. (ADMA)
 
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty biologics and human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com.
 
Use of Non-GAAP Financial Measures
 
This press release includes certain non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The Company believes Adjusted EBITDA is useful to investors in evaluating the Company’s financial performance. The Company uses Adjusted EBITDA as a key performance measure because we believe that it facilitates operating performance comparisons from period to period that exclude potential differences driven by the impact of variations of non-cash items such as depreciation and amortization, as well as stock-based compensation or certain non-recurring items. The Company believes that investors should have access to the same set of tools used by our management and board of directors to assess our operating performance. Adjusted EBITDA should not be considered as a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing the Company’s financial performance. Accordingly, this key business metric has limitations as an analytical tool. It should not be considered as an alternative to net income/loss or any other performance measures derived in accordance with GAAP and may be different from similarly titled non-GAAP measures used by other companies. Please refer to the tables below for the reconciliation of GAAP measures to non-GAAP measures for applicable periods.
 
Cautionary Note Regarding Forward-Looking Statements
 
This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “confident,” “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “is likely,” “will likely,” “should,” “could,” “would,” “may,” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements about the Company’s financial health, standing and future results of operations, including, but not limited to, revenue, net income and Adjusted EBITDA guidance in future periods, and certain assumptions in connection therewith; the market for ASCENIV, its potential impact on revenues and margin expansion; the utility of ADMAlytics and its impact on the Company’s earnings growth outlook; and additional growth opportunities, including but not limited to, targeting certain patient populations, the Company’s yield enhancement initiative and production processes and the timing related thereto, and the Company’s R&D program, including the newly announced hIG pipeline program targeting S. pneumonia (including the revenue potential) and ASCENIV label expansion. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.
 
INVESTOR RELATIONS CONTACT:
Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com
ADMA BIOLOGICS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS


   
June 30,
2024
      
December 31,
2023
   
   
(Unaudited)
        
   
(In thousands, except share data)
  
ASSETS
            
Current assets:
            
Cash and cash equivalents
  
$
88,244
    
$
51,352
  
Accounts receivable, net
    
30,113
      
27,421
  
Inventories
    
179,810
      
172,906
  
Prepaid expenses and other current assets
    
5,524
      
5,334
  
Total current assets
    
303,691
      
257,013
  
Property and equipment, net
    
54,326
      
53,835
  
Intangible assets, net
    
479
      
499
  
Goodwill
    
3,530
      
3,530
  
Right-to-use assets
    
9,152
      
9,635
  
Deposits and other assets
    
5,221
      
4,670
  
TOTAL ASSETS
  
$
376,399
    
$
329,182
  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY
                
Current liabilities:
                
Accounts payable
  
$
14,179
    
$
15,660
  
Accrued expenses and other current liabilities
    
27,726
      
32,919
  
Current portion of deferred revenue
    
1,130
      
182
  
Current portion of lease obligations
    
1,142
      
1,045
  
Total current liabilities
    
44,177
      
49,806
  
Senior notes payable, net of discount
    
131,074
      
130,594
  
Deferred revenue, net of current portion
    
1,619
      
1,690
  
End of term fee
    
1,688
      
1,688
  
Lease obligations, net of current portion
    
9,182
      
9,779
  
Other non-current liabilities
    
390
      
419
  
TOTAL LIABILITIES
    
188,130
      
193,976
  
                 
COMMITMENTS AND CONTINGENCIES
                
                 
STOCKHOLDERS’ EQUITY
                
Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding
     -
       -
  
Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, 233,026,736 and 226,063,032 shares issued and outstanding at June 30, 2024 and December 31, 2023
    
23
      
23
  
Additional paid-in capital
    
644,634
      
641,439
  
Accumulated deficit
    
(456,388
)
    
(506,256
)
TOTAL STOCKHOLDERS’ EQUITY
    
188,269
      
135,206
  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
  
$
376,399
    
$
329,182
  

ADMA BIOLOGICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

 
Three Months ended June 30,
    
Six Months ended June 30,
  
   
2024
    
2023
    
2024
    
2023
  
   
(In thousands, except share and per share data)
  
REVENUES
  
$
107,191
    
$
60,123
    
$
189,066
    
$
117,037
  
Cost of product revenue
    
49,738
      
43,433
      
92,505
      
83,834
  
Gross profit
    
57,453
      
16,690
      
96,561
      
33,203
  
                                 
OPERATING EXPENSES:
                                
Research and development
    
560
      
1,403
      
1,010
      
2,258
  
Plasma center operating expenses
    
942
      
1,333
      
1,947
      
3,114
  
Amortization of intangible assets
    
142
      
179
      
335
      
358
  
Selling, general and administrative
    
16,608
      
14,248
      
32,247
      
28,759
  
Total operating expenses
    
18,252
      
17,163
      
35,539
      
34,489
  
                                 
INCOME (LOSS) FROM OPERATIONS
    
39,201
      
(473
)
    
61,022
      
(1,286
)
                                 
OTHER INCOME (EXPENSE):
                                
Interest income
    
449
      
414
      
833
      
581
  
Interest expense
    
(3,783
)
    
(6,299
)
    
(7,552
)
    
(12,415
)
Other expense
    
(16
)
    
(13
)
    
(51
)
    
(40
)
Other expense, net
    
(3,350
)
    
(5,898
)
    
(6,770
)
    
(11,874
)
                                 
INCOME (LOSS) BEFORE INCOME TAXES
    
35,851
      
(6,371
)
    
54,252
      
(13,160
)
                                 
Provision for income taxes
    
3,789
      
-
      
4,384
      
-
  
                                 
NET INCOME (LOSS)
  
$
32,062
    
$
(6,371
)
  
$
49,868
    
$
(13,160
)
                                 
BASIC EARNINGS (LOSS) PER COMMON SHARE
  
$
0.14
    
$
(0.03
)
  
$
0.22
    
$
(0.06
)
DILUTED EARNINGS (LOSS) PER COMMON SHARE
  
$
0.13
    
$
(0.03
)
  
$
0.21
    
$
(0.06
)
                                 
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
                                
Basic
    
232,417,645
      
222,683,393
      
230,646,246
      
222,304,676
  
Diluted
    
242,167,072
      
222,683,393
      
239,645,940
      
222,304,676
  

NON-GAAP RECONCILIATION
RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA

 
Three Months ended June 30,
    
Six Months ended June 30,
  
 
2024
    
2023
    
2024
    
2023
  
   
(In thousands)
  
Net income (loss)
  
$
32,062
    
$
(6,371
)
  
$
49,868
    
$
(13,160
)
Depreciation
    
1,906
      
1,919
      
3,826
      
3,773
  
Amortization
    
142
      
179
      
335
      
358
  
Income taxes
    
3,789
      
-
      
4,384
      
-
  
Interest expense
    
3,783
      
6,299
      
7,552
      
12,415
  
EBITDA
    
41,682
      
2,026
      
65,965
      
3,386
  
Stock-based compensation
    
2,863
      
1,637
      
5,004
      
2,747
  
IT systems disruption
            
2,770
      
-
      
2,770
  
Adjusted EBITDA
  
$
44,545
    
$
6,433
    
$
70,969
    
$
8,903
  


EX-101.SCH 3 adma-20240808.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 adma-20240808_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 adma-20240808_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image0.jpg begin 644 image0.jpg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image00001.jpg begin 644 image00001.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Document and Entity Information
Aug. 08, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 08, 2024
Entity File Number 001-36728
Entity Registrant Name ADMA BIOLOGICS, INC.
Entity Central Index Key 0001368514
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 56-2590442
Entity Address, Address Line One 465 State Route 17
Entity Address, City or Town Ramsey
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07446
City Area Code 201
Local Phone Number 478-5552
Title of 12(b) Security Common Stock
Trading Symbol ADMA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 22 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://admabiologics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports adma-20240808.xsd adma-20240808_lab.xml adma-20240808_pre.xml ef20033774_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20033774_8k.htm": { "nsprefix": "adma", "nsuri": "http://admabiologics.com/20240808", "dts": { "schema": { "local": [ "adma-20240808.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "adma-20240808_lab.xml" ] }, "presentationLink": { "local": [ "adma-20240808_pre.xml" ] }, "inline": { "local": [ "ef20033774_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://admabiologics.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240808to20240808", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20033774_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240808to20240808", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20033774_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0001140361-24-036399-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-24-036399-xbrl.zip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ef20033774_8k_htm.xml IDEA: XBRL DOCUMENT 0001368514 2024-08-08 2024-08-08 false 0001368514 NASDAQ 8-K 2024-08-08 ADMA BIOLOGICS, INC. DE 001-36728 56-2590442 465 State Route 17 Ramsey NJ 07446 201 478-5552 false false false false Common Stock ADMA false